Endothelin and vascular function in liver disease

Gut

Volumn 53, Issue 2, 2004, Pages 159-161

  Moore, K ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; VASOCONSTRICTOR AGENT;

ACUTE KIDNEY FAILURE; BLOOD VESSEL FUNCTION; HEPATORENAL SYNDROME; HUMAN; KIDNEY FAILURE; LIVER BLOOD VESSEL; LIVER CIRRHOSIS; LIVER DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ENDOTHELINS; HEPATORENAL SYNDROME; HUMANS; LIVER CIRRHOSIS; MUSCLE, SMOOTH, VASCULAR; PORTAL PRESSURE; RATS; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B;

EID: 1642492963     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2003.024703     Document Type: Review

References (33)

1. Yanigasawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by. Nature 1988;332:411-15.
2. La M, Reid JJ. Endothelin-1 and the regulation of vascular tone. Clin Exp Pharmacol Physiol 1995;22:315-23.
3. Firth JD, Ratcliffe PJ, Raine AE, et al. Endothelin: an important factor in acute renal failure? Lancet 1988;2:1179-82.
4. Ring-Larsen H. Renal blood flow in cirrhosis: relation to systemic and portal haemodynamics and liver function. Scand J Clin Lab Invest 1977;37:635-42.
5. Simonson MS, Dunn MJ. Endothelin-1 stimulates contraction of rat glomerular mesangial cells and potentiates beta-adrenergic-mediated cyclic adenosine monophosphate accumulation. J Clin Invest 1990;85:790-7.
6. Gulberg V, Gerbes AL, Vollmar AM, et al. Endothelin-3 like immunoreactivity in plasma of patients with cirrhosis of the liver. Life Sci 1992;51:1165-9.
7. Uemasu J, Matsumoto H, Kawasaki H. Increased plasma endothelin levels in patients with liver cirrhosis. Nephron 1992;60:380.
8. Moore K, Wendon J, Frazer M, et al. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med 1992;327:1774-8.
9. Bachmann-Brandt S, Bittner I, Neuhaus P, et al. Plasma levels of endothelin-1 in patients with the hepatorenal syndrome after successful liver transplantation. Transpl Int 2000;13:357-62.
10. Kapoor D, Redhead DN, Hayes PC, et al. Systemic and regional changes in plasma endothelin following transient increase in portal pressure. Liver Transplant 2003;9:32-9.
11. Anand R, Harry D, Holt S, et al. Endothelin is an important determinant of renal function in a rat model of acute liver and renal failure. Gut 2002;50:111-17.
12. Ghandhi CR, Stephenson K, Olson MS. Endothelin, a potent peptide agonist in the liver. J Biol Chem 1990;265:17432-5.
13. 2+ oscillations, and activation of glycogenolysis. J Clin Invest 1991;87:133-8.
14. Pinzani M, Gentilini P. Biology of hepatic stellate cells and their possible relevance in the pathogenesis of portal hypertension in cirrhosis. Semin Liver Dis 1999;19:397-410.
15. Pinzani M, Marra F, Carloni V. Signal transduction in hepatic stellate cells. Liver 1998;18:2-13.
16. Rockey DC. Characterization of endothelin receptors mediating rat hepatic stellate cell contraction. Biochem Biophys Res Commun 1995;207:725-31.
17. Rockey DC, Weisiger RA. Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance. Hepatology 1996;24:233-40.
18. Kawada N, Kuroki T, Kobayashi K, et al. Action of endothelins on hepatic stellate cells. J Gastroenterol 1995;30:731-8.
19. Kawada N, Tran-Thi TA, Klein H, et al. The contraction of hepatic stellate (lto) cells stimulated with vasoactive substances. Possible involvement of endothelin 1 and nitric oxide in the regulation of the sinusoidal tonus. Eur J Biochem 1993;213:815-23.
20. Pinzani M, Milani S, De Franco R, et al. Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. Gastroenterology 1996;110:534-48.
21. Yokomori H, Oda M, Yasogawa Y, et al. Enhanced expression of endothelin B receptor at protein and gene levels in human cirrhotic liver. Am J Pathol 2001;159:1353-62.
22. Alam I, Bass NM, Bacchetti P, et al. Hepatic tissue endothelin-1 levels in chronic liver disease correlate with disease severity and ascites. Am J Gastroenterol 2000;95:199-203.
23. Leivas A, Jimenez W, Bruix J, et al. Gene expression of endothelin-1 and ET(A) and ET(B) receptors in human cirrhosis: relationship with hepatic hemodynamics. J Vasc Res 1998;35:186-93.
24. Gerbes AL, Moller S, Gulberg V, et al. Endothelin-1 and -3 plasma concentrations in patients with cirrhosis: role of splanchnic and renal passage and liver function. Hepatology 1995;21:735-9.
25. Moller S, Gulberg V, Henriksen JH, et al. Endothelin-1 and endothelin-3 in cirrhosis: relations to systemic and splanchnic haemodynamics. J Hepatol 1995;23:135-44.
26. Nagasue N, Dhar DK, Yamanoi A, et al. Production and release of endothelin-1 from the gut and spleen in portal hypertension due to cirrhosis. Hepatology 2000;31:1107-14.
27. Pannen BH, Bauer M, Zhang JX, et al. Endotoxin pretreatment enhances portal venous contractile response to endothelin-1. Am J Physiol 1996;270(1 pt 2):H7-15.
28. Yokoyama Y, Baveja R, Kresge N, et al. Endothelin receptor remodeling induces the portal venous hyper-response to endothelin-1 following endotoxin pretreatment. Shock 2002;17:36-40.
29. Reichen J, Gerbes AL, Steiner MJ, et al. The effect of endothelin and its antagonist Bosentan on hemodynamics and microvascular exchange in cirrhotic rat liver. J Hepatol 1998;28:1020-30.
30. Kojima H, Yamao J, Tsujimoto T, et al. Mixed endothelin receptor antagonist, SB209670, decreases portal pressure in biliary cirrhotic rats in vivo by reducing portal venous system resistance. J Hepatol 2000;32:43-50.
31. Helmy A, Jalan R, Newby DE, et al. Altered peripheral vascular responses to exogenous and endogenous endothelin-1 in patients with well-compensated cirrhosis. Hepatology 2001;33:826-31.
32. Helmy A, Newby DE, Jalan R, et al. Enhanced vasodilatation to endothelin antagonism in patients with compensated cirrhosis and the role of nitric oxide. Gut 2003;52:410-15.
33. Vaughan RB, Angus PW, Chin-Dusting JP. Evidence for altered vascular responses to exogenous endothelin-1 in patients with advanced cirrhosis with restoration of the normal vasoconstrictor response following successful liver transplantation. Gut 2003;52:1505-10.